Platform Technology Overview

CoImmune is developing 2 platform technologies

Our CAR-CIK technology is currently being developed for liquid tumors and our RNA-loaded dendritic cell technology for solid tumors. Our first CAR-CIK product is currently in clinical trials in pediatric and adult acute lymphoblastic leukemia and our first dendritic cell product is currently in a clinical trial in advanced metastatic renal cell carcinoma.

Allogeneic CAR-modified cytokine induced killer (CIK) cell*
  • Multiple killing mechanisms
  • Strong efficacy in prior trial with little to no toxicity
  • Allogeneic with off-the-shelf availability
  • Proprietary non-viral gene transfer
  • Broad applicability in both liquid and solid tumors
  • Lower cost of goods compared to approved CAR-T

  *Experimental Hematology 34 (2006) 1218-1228
**J Immunother (2011) 34 (1):45-57

Autologous RNA-loaded dentritic cells **
  • Targets all neoantigens without the need to identify them
  • Strong efficacy in prior trial
  • Little to no toxicity
  • Broadly applicable to all solid tumors